^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MT-8421

i
Other names: MT-8421, ETB targeting CTLA-4, CTLA-4 ETB, CTLA-4 targeting ETB Program, CTLA-4-targeted ETB
Associations
Company:
Molecular Templates
Drug class:
CTLA4 inhibitor
Associations
21d
MT-8421-001: Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types (clinicaltrials.gov)
P1, N=15, Terminated, Molecular Templates, Inc. | Active, not recruiting --> Terminated; Sponsor Termination
Trial termination
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
MSI-H/dMMR
|
Opdivo (nivolumab) • MT-8421
1m
MT-8421-001: Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types (clinicaltrials.gov)
P1, N=15, Active, not recruiting, Molecular Templates, Inc. | Recruiting --> Active, not recruiting | N=200 --> 15 | Trial completion date: Oct 2026 --> Oct 2024 | Trial primary completion date: Jul 2026 --> Oct 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
MSI-H/dMMR
|
Opdivo (nivolumab) • MT-8421
1year
New P1 trial • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
MSI-H/dMMR
|
Opdivo (nivolumab) • MT-8421